/
ADMA
$8.70-$0.04 (-0.46%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.0B
232M shares
52-week range
$7.21 – $20.46
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$7.08
ADMA Biologics, Inc.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
www.admabiologics.com- Employees
- 647
- IPO / List date
- Oct 17, 2013
- HQ
- RAMSEY, NJ
Held by traders on TradeandTell
No one on the platform currently holds ADMA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,262,634 | $11.4M |
| Bridgewater Associatesas of 2026-03-31 | 472,108 | $4.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ADMA yet.
